Silexion Cancer Drug Achieves 97% Tumor Inhibition, Tackles Previously Resistant Mutation

Silexion Therapeutics (NASDAQ: SLXN) has announced breakthrough preclinical data for its RNA interference therapy SIL204, demonstrating exceptional cancer cell growth inhibition rates. The study showed up to 97% inhibition in pancreatic cancer cells and 90% in colorectal cancer cells, including first-time evidence against the KRAS Q61H mutation.

Key findings revealed dose-dependent inhibition of up to 94% in pancreatic cancer cells with KRAS G12D mutations, 97% inhibition in pancreatic cancer cells with KRAS Q61H mutations, and nearly 90% inhibition in colorectal cancer cells with KRAS G12D mutations. The company is preparing for a Phase 2/3 clinical trial in Q2 2026 to investigate SIL204 for KRAS-driven solid tumor cancers.

https://www.stocktitan.net/news/SLXN/silexion-therapeutics-announces-new-preclinical-data-showing-up-to-e291cnoqda4d.html